XORTX Therapeutics (XRTX) Asset Utilization Ratio (2022 - 2023)

XORTX Therapeutics (XRTX) posted Asset Utilization Ratio of 0.8 for Q3 2023, up 22.53% on a QoQ basis from 0.65 in Q2 2023.

XORTX Therapeutics (XRTX) Asset Utilization Ratio (2022 - 2023) Analysis & Trends

XORTX Therapeutics' Asset Utilization Ratio history runs 2 years deep, the most recent figure standing at 0.8 for Q3 2023.

Quarterly Asset Utilization Ratio changed N/A year-over-year to 0.8 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was 0.8 (changed N/A YoY) and the FY2023 annual result came in at 0.22, up 68.18% from the prior year.
Asset Utilization Ratio was 0.8 for Q3 2023 at XORTX Therapeutics, up from 0.65 in the prior quarter.
Across five years, Asset Utilization Ratio topped out at 0.8 in Q3 2023 and bottomed at 0.49 in Q1 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Oculis Holding AG	66,801.52 Bn	66,801.23 Bn	-	-
2	Nanobiotix	1,916.61 Bn	1,916.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.65 Bn	466.85 Bn	1.35 Bn	0.69
5	Vertex Pharmaceuticals	121.94 Bn	114.69 Bn	2.59 Bn	0.47
6	Regeneron Pharmaceuticals	69.85 Bn	61.09 Bn	3.31 Bn	0.37
7	Belite Bio	63.06 Bn	63.06 Bn	-	-
8	Argenx Se	55.74 Bn	50.56 Bn	1.41 Bn	-
9	Revolution Medicines	37.48 Bn	37.48 Bn	-	-
10	XORTX Therapeutics	2.91 Bn	2.91 Bn	-	-

Download Data